Loading…
The filing was made to protect the company's intellectual property in the field of immunotherapy.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) filed a patent application for "Identification Of Neoantigen-Reactive T Cell Receptors". The application aims to secure intellectual property rights for the company's advancements in immunotherapy.
The patent application details the identification and characterization of T cell receptors that react to neoantigens, which are novel antigens formed by mutations in cancer cells. This technology could potentially enhance the specificity and efficacy of T cell-based immunotherapies.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.